Parallax Volatility Advisers
HRTX icon

Parallax Volatility Advisers’s Heron Therapeutics HRTX Stock Holding History

Parallax Volatility Advisers’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-6,888
Closed -$125K – 3112
2017
Q4 		$125K Buy
6,888
+4,307
+167% +$70.2K ﹤0.01% 2651
2017
Q3 		$42K Buy
2,581
+1,982
+331% +$31.1K ﹤0.01% 1659
2017
Q2 		$8K Hold
599
– – ﹤0.01% 2003
2017
Q1 		$9K Hold
599
– – ﹤0.01% 3194
2016
Q4 		$8K Hold
599
– – ﹤0.01% 2813
2016
Q3 		$10K Buy
+599
New +$11.1K ﹤0.01% 2671
2016
Q2 		– Sell
-599
Closed -$11.7K – 2929
2016
Q1 		$11K Sell
599
-2,100
-78% -$41.4K ﹤0.01% 2332
2015
Q4 		$72K Buy
+2,699
New +$72.2K ﹤0.01% 2231

Other funds holding HRTX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Parallax Volatility Advisers's HRTX Position: Q1 2018 in Review

Parallax Volatility Advisers sold out of Heron Therapeutics (HRTX) in Q1 2018, closing a stake of 6,888 shares — an estimated $125K sold.

Parallax Volatility Advisers first reported a position in HRTX in Q4 2015 and held it in 8 quarters. The position peaked at $125K in Q4 2017. 152 funds tracked by Wall St. Rank hold HRTX as of Q1 2018.

  • Parallax Volatility Advisers reported no remaining Heron Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Parallax Volatility Advisers sold 6,888 Heron Therapeutics shares in Q1 2018, an estimated $125K.
  • Parallax Volatility Advisers first reported a position in Heron Therapeutics in Q4 2015 and held it in 8 quarters.
  • Parallax Volatility Advisers's Heron Therapeutics position peaked at $125K in Q4 2017.
  • 152 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2018.

Based on Parallax Volatility Advisers's 13F filing for Q1 2018, filed 15 May 2018.